HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
作者信息
Shofuda Tomoko, Kanemura Yonehiro
机构信息
Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Department of Neurosurgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
出版信息
Neuro Oncol. 2021 Feb 25;23(2):173-174. doi: 10.1093/neuonc/noaa292.
Abstract
摘要
相似文献
1
HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?髓母细胞瘤中的组蛋白去乙酰化酶（HDACs）与MYC：HDAC抑制剂如何控制MYC扩增的肿瘤？
Neuro Oncol. 2021 Feb 25;23(2):173-174. doi: 10.1093/neuonc/noaa292.
2
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.一种针对 3 组（MYC 驱动）髓母细胞瘤中 BET 蛋白和组蛋白去乙酰化酶的新型双重表观遗传学方法。
J Exp Clin Cancer Res. 2022 Nov 11;41(1):321. doi: 10.1186/s13046-022-02530-y.
3
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.组蛋白去乙酰化酶抑制导致 MYC 扩增型髓母细胞瘤中 MYC 染色质结合减少。
Neuro Oncol. 2021 Feb 25;23(2):226-239. doi: 10.1093/neuonc/noaa191.
4
Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.联合药物筛选鉴定了 BCL-XL 和 I 类组蛋白去乙酰化酶抑制剂在 MYC 扩增型髓母细胞瘤细胞中的协同药物相互作用。
J Neurooncol. 2024 Jan;166(1):99-112. doi: 10.1007/s11060-023-04526-w. Epub 2024 Jan 7.
5
Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.极光激酶B抑制在MYC过表达的髓母细胞瘤中的作用机制及治疗效果
Oncotarget. 2015 Feb 20;6(5):3359-74. doi: 10.18632/oncotarget.3245.
6
Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.组 3（MYC 驱动）髓母细胞瘤中蛋白质精氨酸甲基转移酶 5 的作用。
BMC Cancer. 2019 Nov 6;19(1):1056. doi: 10.1186/s12885-019-6291-z.
7
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.BET 抑制剂 MK-8628 与 PLK 抑制剂 Volasertib 在髓母细胞瘤临床前模型中的协同作用。
Cancer Lett. 2019 Mar 31;445:24-33. doi: 10.1016/j.canlet.2018.12.012. Epub 2019 Jan 4.
8
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.I 类组蛋白去乙酰化酶抑制可降低 MYC 扩增型髓母细胞瘤细胞的 DNA 损伤修复能力。
J Neurooncol. 2023 Sep;164(3):617-632. doi: 10.1007/s11060-023-04445-w. Epub 2023 Oct 3.
9
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.联合 BET 溴结构域和 CDK2 抑制在 MYC 驱动的髓母细胞瘤中。
Oncogene. 2018 May;37(21):2850-2862. doi: 10.1038/s41388-018-0135-1. Epub 2018 Mar 7.
10
OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.Olig2 是 MYC 扩增型髓母细胞瘤复发的决定因素。
Clin Cancer Res. 2022 Oct 3;28(19):4278-4291. doi: 10.1158/1078-0432.CCR-22-0527.
引用本文的文献
1
Epigenetic modifications and their roles in pediatric brain tumor formation: emerging insights from chromatin dysregulation.表观遗传修饰及其在儿童脑肿瘤形成中的作用：染色质失调的新见解
Front Oncol. 2025 Jun 17;15:1569548. doi: 10.3389/fonc.2025.1569548. eCollection 2025.
2
The Role of Chronic Inflammation in Pediatric Cancer.慢性炎症在儿童癌症中的作用。
Cancers (Basel). 2025 Jan 6;17(1):154. doi: 10.3390/cancers17010154.
3
Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas.具有新型 MYC 扩增的侵袭性小儿脊髓室管膜瘤与新描述的 MYCN 扩增性脊髓室管膜瘤在分子和组织病理学上具有相似性。
Acta Neuropathol Commun. 2021 Dec 11;9(1):192. doi: 10.1186/s40478-021-01296-2.
4
Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.脑肠肽受体家族激活与中枢神经系统/神经肿瘤：支持新型靶向治疗可能作用的证据综述。
Front Endocrinol (Lausanne). 2021 Sep 1;12:728088. doi: 10.3389/fendo.2021.728088. eCollection 2021.
5
Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment.用于脑癌干细胞的表观遗传调节剂：对抗癌治疗的意义。
World J Stem Cells. 2021 Jul 26;13(7):670-684. doi: 10.4252/wjsc.v13.i7.670.
本文引用的文献
1
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.组蛋白去乙酰化酶抑制导致 MYC 扩增型髓母细胞瘤中 MYC 染色质结合减少。
Neuro Oncol. 2021 Feb 25;23(2):226-239. doi: 10.1093/neuonc/noaa191.
2
Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential.组蛋白去乙酰化酶抑制剂在儿童脑癌中的作用：生物学活性与治疗潜力
Front Cell Dev Biol. 2020 Jul 10;8:546. doi: 10.3389/fcell.2020.00546. eCollection 2020.
3
HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma.组蛋白去乙酰化酶和 MAPK/ERK 抑制剂协同作用降低髓母细胞瘤的活力和干性。
J Mol Neurosci. 2020 Jun;70(6):981-992. doi: 10.1007/s12031-020-01505-y. Epub 2020 Feb 13.
4
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.分子时代儿童髓母细胞瘤的风险分层：当前共识
Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4.
5
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.HDAC 和 PI3K 拮抗剂协同抑制 MYC 驱动的髓母细胞瘤生长。
Cancer Cell. 2016 Mar 14;29(3):311-323. doi: 10.1016/j.ccell.2016.02.011.
6
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.靶向 MYC 扩增组 3 型髓母细胞瘤中的 I 类组蛋白去乙酰化酶 2。
Acta Neuropathol Commun. 2015 Apr 3;3:22. doi: 10.1186/s40478-015-0201-7.
7
Molecular subgroups of medulloblastoma: the current consensus.髓母细胞瘤的分子亚型：当前共识。
Acta Neuropathol. 2012 Apr;123(4):465-72. doi: 10.1007/s00401-011-0922-z. Epub 2011 Dec 2.
8
The many roles of histone deacetylases in development and physiology: implications for disease and therapy.组蛋白去乙酰化酶在发育和生理学中的多种作用：对疾病和治疗的影响。
Nat Rev Genet. 2009 Jan;10(1):32-42. doi: 10.1038/nrg2485.
Zotero 插件